

REV. 9/00
For A Small Entity



VPI/97-2004 CON

RECEIVED
MAR 06 2001
TECH CENTER 1000/2300

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned
Group : 1653
Applicants : Michael S. Su et al.
Serial No. : 09/642,749
Filed : August 18, 2000
For : METHODS FOR DESIGNING INHIBITORS OF
SERINE/THREONINE KINASES AND TYROSINE
KINASES

New York, New York
February 26, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

Transmitted herewith: ☒ a Supplemental Preliminary Amendment; ☐ a Reply to Office Action; ☐ a Supplemental Amendment; ☐ a substitute Specification; ☐ a Declaration; ☐ a Supplemental Declaration; ☐ a Power of Attorney; ☐ an Associate Power of Attorney; ☐ formal drawings; to be filed in the above-identified patent application.

FEE FOR ADDITIONAL CLAIMS

☐ A fee for additional claims is not required.

[X] A fee for additional claims is required.



The additional fee has been calculated as shown below:

	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NUMBER PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE	ADDITIONAL FEES
TOTAL CLAIMS	25	-	20	* = 5		X \$ 9 =	\$45.00
INDEPENDENT CLAIMS	2	-	3	** = 0		X \$ 40 =	\$0
FIRST PRESENTATION OF A MULTIPLE DEPENDENT CLAIM						+ \$135 =	\$0
* If less than 20, insert 20.					TOTAL		<u>\$45.00</u>
** If less than 3, insert 3.							

[] A check in the amount of \$_____ in payment of the filing fee is transmitted herewith.

[X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16, in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

[X] Please charge \$45.00 to Deposit Account No. 06-1075 in payment of the filing fee. A duplicate copy of this transmittal letter is transmitted herewith.

EXTENSION FEE

[] The following extension is applicable to the Response filed herewith; [] \$55.00 extension fee for response within first month pursuant to 37 C.F.R. § 1.136(a); [] \$195.00 extension fee for response within second month pursuant to 37 C.F.R. § 1.136(a); [] \$445.00 extension fee for response within third month pursuant to 37 C.F.R. § 1.136(a); [] \$695.00 extension fee for



response within fourth month pursuant to 37 C.F.R. § 1.136 (a); ☐ \$945.00 extension fee for response within fifth month pursuant to 37 C.F.R. 1.136(a).

☐ A check in the amount of ☐ \$55.00; ☐ \$195.00; ☐ \$445.00; ☐ \$695.00; ☐ \$945.00; in payment of the extension fee is transmitted herewith.

☒ The Commissioner is hereby authorized to charge payment of any additional fees required under 37 C.F.R. § 1.17 in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

☐ Please charge the ☐ \$55.00; ☐ \$195.00; ☐ \$445.00; ☐ \$695.00; ☐ \$945.00; extension fee to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

Karen E. Brown

James F. Haley, Jr. (Reg. No. 27,794)
Attorney for Applicants

Karen E. Brown (Reg. No. 43,866)

Agent for Applicants

c/o Fish & Neave

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax: (212) 596-9090

I hereby certify that this
communication is being
submitted with the U.S.
Patent application on file
Class 1.136 in an envelope
marked for
COMMERCIAL FOR
RECORD
WASHINGTON, D.C. 20231 on

February 26, 2001

Lori N. Scott

Lori N. Scott
Signature of Person Signing




#713
3-14-01
32

VPI/97-104 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned
Group : 1653
Applicants : Michael S. Su et al.
Serial No. : 09/642,749
Filed : August 18, 2000
For : METHODS FOR DESIGNING INHIBITORS OF
SERINE/THREONINE KINASES AND TYROSINE
KINASES



New York, New York
February 26, 2001

Hon. Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL PRELIMINARY AMENDMENT

Sir:

Prior to examining this application, please amend the application as follows:

IN THE CLAIMS

Please amend claims 16 and 17 as follows:*

B₁
16. (Twice amended) The crystallizable co-complex according to claim 15, wherein said first protein kinase is p38, said second protein kinase is a MAP kinase and said inhibitor is a pyridinyl-imidazole inhibitor of p38.

* An "Appendix of Amendments" is enclosed at Tab A, showing the amendments to the claims. In the Appendix, the added portions are underscored and the deleted portions are bracketed.